multicenter study

Related by string. Multicenter Study * Multicenter : multicenter randomized double . multicenter Phase II . Multicenter Randomized Double . multicenter clinical . multicenter randomized . label multicenter / studying . Studying . STUDY . studys . STUDYING . stu dy : Pre Feasibility Study . Case Study . Study Shows . Study Reveals . Study Confirms * prospective multicenter study *

Related by context. All words. (Click for frequent words.) 77 randomized controlled trial 75 multicenter 75 prospective observational 75 randomized clinical 72 multicentre study 71 randomized controlled 71 observational study 70 prospective randomized 70 retrospective cohort study 70 multicentre 69 multicenter clinical 69 prospective cohort 69 substudy 67 prospective multicenter 67 retrospective observational study 67 multicenter prospective 67 clinical trial 67 longitudinal study 67 randomized controlled clinical 67 randomized multicenter trial 67 randomized placebo controlled 66 multicenter phase 66 randomized multicenter 66 longitudinal cohort study 66 placebo controlled 66 multicenter randomized 66 randomized trials 66 prospective randomized controlled 66 randomized double 66 placebo controlled Phase III 66 multicenter randomized clinical 66 randomized 65 multicentre randomized 65 double blinded randomized 65 multicenter randomized double 65 multicenter Phase II 65 Phase IIIb study 65 placebo controlled clinical 64 randomized clinical trials 64 meta analysis 64 blind randomized 64 randomized Phase III 64 multicentre randomized double 64 Phase III randomized 64 Phase 2b study 64 blind randomized placebo 64 RE LY ® 64 retrospective cohort 64 Clinical Antipsychotic Trials 64 phase IIb trial 63 liver transplant recipients 63 double blind placebo 63 placebo controlled randomized 63 multicenter trials 63 multicenter randomized controlled 63 subanalysis 63 Prostate Lung Colorectal 63 Phase IIb trial 63 observational cohort study 63 TMC# C# 63 NO# [002] 63 phase IIb clinical 63 prospective longitudinal 62 blind placebo controlled 62 Carotid Revascularization Endarterectomy vs. 62 ExTRACT TIMI 62 prospective randomized multicenter 62 Screening Trial 62 randomized controlled trials 62 multicenter placebo controlled 62 placebo controlled trials 62 multicenter Phase 62 nonrandomized 62 study 62 Atherosclerosis MESA 61 placebo controlled studies 61 phase IIa 61 trials RCTs 61 Multicenter 61 EORTC 61 Phase III randomized controlled 61 randomized blinded 61 placebo controlled Phase 61 blinded placebo controlled 61 AIR2 Trial 61 prospective multicenter study 61 HCV SPRINT 61 dose escalation study 61 prospective nonrandomized 61 NCCTG 61 HeFT 61 Multiethnic Study 60 Digital Mammographic Imaging 60 multicenter randomized placebo controlled 60 NICE SUGAR 60 Communities ARIC study 60 RE LY 60 clinical pharmacology studies 60 phase IIIb 60 Randomized Evaluation 60 HORIZONS AMI trial 60 label multicenter 60 controlled multicenter 60 REALITY Trial 60 CALGB 60 randomized blinded placebo 60 phase IIb 60 prospective multicentre 60 Ovarian PLCO Cancer 60 prospective observational cohort 60 ABSORB trial 60 phase IIa clinical 60 Stenting Trial CREST 60 Phase Ib clinical 60 Multi Ethnic Study 60 randomized Phase IIb 60 blinded randomized 60 randomized controlled Phase 59 multicenter Phase III 59 prospective randomized placebo 59 TG MV 59 Sorafenib HCC Assessment 59 Group RTOG 59 Phase 2b trial 59 multicentre prospective 59 randomized controlled clinical trials 59 Edge STudy 59 Framingham Offspring Study 59 patients undergoing percutaneous 59 dose escalation trial 59 MADIT CRT trial 59 RE LY trial 59 multicenter clinical trials 59 Intervention Trial GAIT 59 double blinded placebo 59 INTERHEART study 59 hemodialysis patients 59 Phase 2a trial 59 DAPT Study 59 Radiation Therapy Oncology 59 AVERROES 59 Multicentre 59 subgroup analyzes 59 Phase 2b clinical 59 multicenter multinational 59 Phase IIIb clinical 59 phase IIb study 59 postmenopausal women 58 dose escalation clinical 58 RTOG 58 HPTN 58 Gynecologic Oncology Group 58 TAXUS ATLAS 58 LUX Lung 58 Phase 1b trial 58 Amrubicin 58 Dialysis Outcomes 58 OLYMPIA registry 58 Heart Failure Trial 58 Phase IIa trial 58 CARE HF 58 ONTARGET 58 EchoCRT 58 placebo controlled clinical trials 58 CLARITY study 58 CHAMPION PCI 58 Alzheimer Disease Neuroimaging Initiative 58 ELCAP 58 dose dose escalation 58 riociguat 58 PLCO 58 Ovarian Cancer Screening 58 CLL8 58 observational studies 58 International Verapamil SR 58 MADIT II 58 ADVANCE PD 58 dabigatran etexilate 58 landmark ATHENA 58 recurrent GBM 58 RIO Lipids 58 EVEREST II 58 phase III ACCLAIM 58 Multicenter Study 58 Phase IIIb 58 Intervention Effectiveness CATIE 58 pivotal bioequivalence 58 Phase 2a clinical 58 BR.# 58 Nutrition EPIC 58 MGd 58 blind randomized controlled 58 viral kinetic 58 INTERCEPT platelets 58 Phase IIb 58 transplantation HSCT 58 Prospective Investigation 58 ENESTnd 57 SPIRIT IV 57 Endeavor Resolute DES 57 clinical trials 57 Atherosclerosis Risk 57 VITAL Trial 57 Phase III clinical 57 TAXUS V 57 Intervention Trial 57 ECASS 57 BOLDER II 57 randomized multicenter Phase III 57 Phase IIB 57 EURIDIS 57 ToGA 57 CYPHER R Sirolimus eluting 57 NSABP B 57 active comparator 57 TAXUS IV 57 dose escalation Phase 57 ENDEAVOR IV 57 study1 57 Swedish Mammography Cohort 57 VADT 57 Intervention Effectiveness 57 Val HeFT 57 Wisconsin Sleep Cohort 57 Prospective Randomized 57 prospectively randomized 57 Screening Trial DMIST 57 blinded randomized placebo controlled 57 symptomatic BPH 57 TAXUS VI 57 BRIM3 57 IMPROVE HF 57 DAPT 57 Phase Ib study 57 phase Ib 57 blind multicenter 57 DMIST 57 Randomized Study 57 masked placebo controlled 57 recurrent malignant glioma 57 longitudinal studies 56 neoadjuvant 56 paclitaxel eluting stents 56 oral deforolimus 56 AIM HIGH 56 Acute Ischemic Stroke 56 PERSEUS clinical program 56 underwent liver transplantation 56 BCIRG 56 ACUITY trial 56 Pivotal Trial 56 ADAGIO study 56 everolimus eluting stent 56 CardioFit 56 Phase Ib II 56 randomized Phase 56 Cardiac Allograft Rejection 56 noninferiority 56 Phase Ib 56 GEM OS1 56 Phase 1b clinical 56 Feasibility Trial 56 Degarelix 56 MAGE A3 ASCI 56 STRIDE PD 56 PICSO ® 56 SWOG 56 APEX AMI trial 56 ELACYT 56 acute coronary syndromes ACS 56 rALLy clinical trial 56 retrospectively analyzed 56 Communities ARIC Study 56 multicentric 56 Cochrane Systematic Review 56 Edwards SAPIEN valve 56 recurrent glioblastoma multiforme 56 SYNTAX trial 56 blind placebo 56 randomized crossover 56 undergone radical prostatectomy 56 adjuvant tamoxifen 56 ABCSG 56 Phase #/#a 56 ASCEND HF 56 nab paclitaxel 56 chemoradiotherapy 56 longitudinal observational study 56 BARI 2D 56 CAMMS# 56 Cholesterol Levels SPARCL 56 pharmacokinetic PK 56 Myocardial Infarction Study 56 DCCT 56 bronchial thermoplasty 56 SPIRIT III 56 HCV RESPOND 2 56 Zilver PTX 56 REGARDS 56 genomewide association study 56 controlled dose escalation 56 Aggressive Reduction 56 Phase III VISTA 56 Phase III trials 55 carotid artery stenting 55 Study ADCS 55 adenotonsillectomy 55 NHANES III 55 ACOSOG Z# 55 pharmacokinetic studies 55 RSD# oral 55 Prostate Cancer Prevention 55 Phase III pivotal 55 PFO migraine 55 Evaluation WISE 55 liver resection 55 pain palliation 55 prospective multicenter randomized 55 Phase IIb clinical trials 55 Phase III metastatic melanoma 55 Study AREDS 55 registrational trial 55 Clinical Outcomes Utilizing Revascularization 55 Phase 1b clinical trials 55 Myocardial Infarction 55 pivotal Phase III 55 number NCT# ClinicalTrials.gov 55 AIR CF3 55 radical cystectomy 55 Angiox R 55 prospectively defined 55 AIR CF1 55 carotid artery stenting CAS 55 Sipuleucel T 55 confirmatory clinical 55 iPrEx study 55 observational cohort 55 MADIT CRT 55 TAXUS TM 55 Baltimore Longitudinal Study 55 COMFORT II 55 everolimus eluting stents 55 Women Ischemia Syndrome 55 Subgroup analysis 55 randomized controlled multicenter 55 Patient Registry 55 AIR CF2 55 BRIM2 55 UKPDS 55 SUCCEED trial 55 e HEALING 55 Prospective Randomized Trial 55 Thrombolysis 55 randomized Phase 2b 55 transcatheter aortic valve implantation 55 Phase Ia 55 LHRH receptor positive 55 APTIVUS 55 standard chemotherapy regimen 55 Cooperative Oncology 55 PRECiSE 55 CYPHER Stent 55 Ranolazine 55 nulliparous women 55 treatment naïve genotype 55 phase 2a 55 ENDEAVOR clinical 55 cortical stimulation 55 MIVI III 55 Endovascular Valve Edge 55 EFAPROXYN 55 STICH trial 55 fluvastatin 55 Observational Study 55 dosing cohorts 55 RCTs 54 ACRIN 54 SORT OUT III 54 patients undergoing CABG 54 renal transplantation 54 MERLIN TIMI 54 FDA Investigational Device 54 IMPROVE IT 54 ANCHOR trial 54 SABCS 54 TRANSFORMS 54 MabCampath 54 Sequenced Treatment Alternatives 54 Phase #b/#a 54 Phase IIb clinical 54 pegylated interferon alfa 2b 54 relapsing remitting MS RRMS 54 operable breast cancer 54 Acute Decompensated Heart Failure 54 Sirolimus eluting Coronary Stent 54 trial evaluating PRX# 54 TAXUS Liberte Stent 54 Cohort Study 54 symptomatic VTE 54 OPT CHF 54 ARIXTRA 54 zotarolimus eluting stent 54 Phase III 54 oral ridaforolimus 54 CURRENT OASIS 7 54 PECARN 54 Health Initiative WHI 54 MTWA testing 54 Bucuvalas Inc. 54 metastatic HRPC 54 eluting stent 54 ataluren 54 CaPSURE 54 label dose escalation 54 ASPIRE HIGHER 54 chemoprevention trials 54 Antiviral Therapy 54 Lancet Oncology 54 ROCKET AF 54 placebo controlled dose escalation 54 Phase IIa clinical 54 epidemiologic studies 54 Phase Ib IIa clinical 54 autologous chondrocyte implantation 54 Prospective Multicenter 54 ATIR TM 54 GAMMAGARD 54 ImmuKnow assay 54 CALGB # [002] 54 Multicenter AIDS 54 Stenting Trial 54 Phase 2b kidney transplant 54 PCI ExTRACT TIMI 54 pharmacokinetics PK 54 AERAS-#/Crucell Ad# 54 Randomized Controlled Trial 54 blinded randomized controlled 54 PRoFESS 54 PRECISE 54 TRITON TIMI 54 RG# ITMN 54 CYPHER ® Sirolimus eluting 54 journal Neurology 54 trabedersen 54 confirmatory Phase III 54 AVADO 54 APPRAISE 54 randomized multicentre 54 rFVIIa 54 ConclusionThis 54 pharmacodynamic effects 54 Normative Aging Study 54 Chronic Heart Failure 54 strontium ranelate 54 Subgroup analyzes 54 Phase 2b 54 invasive bladder 54 NATRECOR ® 54 sirolimus eluting stents 54 Hydroxyurea 54 rosuvastatin 54 MEND CABG 54 eptifibatide 54 CARDIA 54 ACTIVE W 54 IIa clinical 54 PFO closure 54 Trandolapril 54 #F FDG PET 54 REVLIMID lenalidomide 54 Meta analyzes 54 SCD HeFT 54 elective PCI 54 RECORD1 54 generalizability 54 Afatinib 54 Randomised 54 ALLHAT 54 composite endpoint 54 BERKELEY CA UroToday.com 54 ALTTO 54 pharmacokinetic PK study 54 duplex ultrasonography 53 STEP BD 53 Controlled Trial 53 doxorubicin docetaxel 53 COPERNICUS 53 lymphadenectomy 53 Acute Myocardial Infarction 53 protease inhibitor PI 53 pegylated liposomal doxorubicin 53 Dr. Kandzari 53 XIENCE V Stent System 53 PERSEUS 53 landmark ATHENA trial 53 metreleptin 53 multicenter randomized Phase III 53 NeuroStar TMS Therapy 53 AIDS Clinical Trials 53 ENDEAVOR II 53 Relieve Depression 53 LUMINATE 53 EMPHASIS HF trial 53 recurrent glioma 53 PRESEPT 53 unresectable liver cancer 53 SYNTAX 53 depsipeptide 53 EDEMA3 53 hepatectomy 53 Randomized Clinical Trial 53 Safinamide 53 Phase III multicenter 53 Rosuvastatin 53 Phase IIa 53 sirolimus eluting 53 Microplasmin 53 Infarct 53 RG# [001] 53 registrational 53 IIa clinical trial 53 Doxil ® 53 postmenopausal osteoporotic women 53 Critical Limb Ischemia CLI 53 prostate cancer CaP 53 viral kinetics 53 relapsed APL 53 CIMZIA TM certolizumab pegol 53 IMPACT DCM 53 treatment naive genotype 53 NSABP 53 FOLOTYN ® 53 Dabigatran 53 Randomized Phase 53 Accelerated Partial Breast Irradiation 53 urothelial cancer 53 non valvular atrial 53 single ascending dose 53 Phase III clinical trials 53 underwent resection 53 olaparib 53 inhibitor RG# 53 IL# PE#QQR 53 desmoteplase 53 metastatic renal cell carcinoma 53 afatinib 53 HCV infected 53 Lipid Lowering Treatment 53 HORIZONS AMI 53 randomized controlled trials RCTs 53 REVIVE Diabetes 53 Elocalcitol 53 PROMUS Element Stent 53 sipuleucel T 53 chemoradiation 53 ASTEROID 53 Prostate AdenoCarcinoma Treatment 53 Phase 1b 53 unstable angina UA 53 RESOLUTE clinical 53 evaluating tivozanib 53 chromium supplementation 53 pertuzumab 53 PROactive study 53 sunitinib malate 53 CUSTOM III 53 anti arrhythmic drug 53 LEXIVA r 53 CombAT 53 neoadjuvant treatment 53 antihypertensive therapy 53 ERSPC 53 pancreatic adenocarcinoma 53 II Clinical Trial 53 Group B CALGB 53 RRMS patients 53 oral rivaroxaban 53 oral anticoagulation 53 polyarticular 53 NSTE ACS 53 CIBMTR 53 onset atrial fibrillation 53 pharmacodynamic profile 53 Kaplan Meier analysis 53 meta analyzes 53 prospectively evaluated 53 Study ADX# 53 metaanalysis 53 CHARISMA trial 53 quadrivalent HPV vaccine 53 MIST II 53 BOLDER 53 HF ACTION 53 Clinical trials 53 ATTRACT 53 PREVAIL 53 Interagency Registry 53 adult chronic ITP 53 Phase III Clinical Trial 53 relapsing multiple sclerosis 53 cilostazol 53 #mg dosing group 53 noninfectious uveitis 53 journal Ophthalmology 53 CRESTOR #mg 53 GISSI HF 53 brivaracetam 53 superficial bladder cancer 53 VFEND 53 acute ischemic stroke 53 ACTEMRA TM 53 Lancet Neurology 53 Outpatient Setting 53 FAME Study 53 Chicago Multidisciplinary Symposium 53 neoadjuvant chemotherapy 53 Controlled Study 53 CYPHER ® Stent 53 GRAVITAS trial 53 INTERHEART 53 PRE SURGE 52 Neoadjuvant 52 neurologic progression 52 Spine Patient Outcomes 52 safety tolerability pharmacokinetic 52 Phase 1a clinical 52 Young Adults CARDIA 52 ENGAGE AF TIMI 52 thetreatment 52 label multicenter Phase 52 PARTNER Trial 52 stage IIIb IV 52 eculizumab therapy 52 Complications Trial 52 darunavir ritonavir 52 warfarin therapy 52 Myocet 52 osteoporotic vertebral compression fractures 52 NCCTG N# 52 ischemic cardiomyopathy 52 coronary revascularization 52 ENDEAVOR III 52 WallFlex Biliary RX 52 bevacizumab Avastin 52 F FDG PET 52 pCR 52 bendamustine 52 NATRECOR R 52 singleton pregnancies 52 Torisel 52 evaluating REVLIMID 52 IIa trial 52 Pivotal Clinical Trial 52 EINSTEIN DVT 52 comorbid psychiatric disorders 52 PROSTVAC TM 52 RoACTEMRA 52 dose escalation 52 Phase IIb III 52 relapsed MM 52 Tanespimycin 52 atherothrombotic disease 52 histologically confirmed 52 CARDIA study 52 Randomized controlled 52 juvenile idiopathic arthritis 52 dietary questionnaires 52 phase Ib clinical 52 WHIMS 52 ACCLAIM 52 transurethral resection 52 Diabetologia 52 Birth Cohort 52 antiretroviral naïve 52 DSMB 52 ascending dose 52 lorcaserin Phase 52 MabThera rituximab 52 EmbraceAC 52 thromboprophylaxis 52 clopidogrel pretreatment 52 radiochemotherapy 52 cardio renal 52 TEMSO 52 NCT# ClinicalTrials.gov 52 Replication NCS R 52 cystectomy 52 Marrow Transplant Research 52 Rheos System 52 morphometric vertebral fractures 52 prognostic variables 52 Aggressive Drug Evaluation 52 PROPEL trial 52 Netherlands Cohort Study 52 adjuvant chemotherapy 52 logistic regression analysis 52 ABSORB clinical 52 HSCT 52 vorinostat 52 HAART regimens 52 PROSTVAC ® 52 landmark ATHENA study 52 Glucosamine Chondroitin Arthritis 52 National Surgical Adjuvant 52 eosinophilic asthma 52 unblinding 52 PreCISe study 52 ritonavir boosted 52 basal bolus regimen 52 MarginProbe 52 PROVENGE sipuleucel T 52 dose cohorts 52 immunohistochemical staining 52 Phase Ib clinical trials 52 INTERPHONE 52 transplantation HCT 52 Denufosol 52 corifollitropin alfa 52 PLCO trial 52 journal Psychotherapy 52 TYGACIL 52 macrovascular disease 52 HeartNet 52 dexpramipexole 52 goserelin 52 OHR/AVR# 52 Betaferon ® 52 biologic therapy 52 Surgical Treatment 52 HIV HCV coinfected 52 label multicenter randomized 52 knee osteoarthritis OA 52 Recurrent Fracture Trial 52 nomogram 52 Cloretazine 52 Group ECOG 52 hepatic resection 52 miglustat 52 irbesartan 52 efficacy endpoint 52 NLX P# 52 ID NCT# 52 Hepatocellular Carcinoma HCC 52 multicentre randomized controlled 52 Randomized 52 T1DM 52 icatibant 52 chest radiographs 52 somatostatin analog 52 League Against Rheumatism 52 mycophenolate mofetil 52 Phase III placebo controlled 52 FDG PET 52 recurrent ovarian cancer 52 Phase III psoriasis 52 ACCOMPLISH 52 dyskinesia PD LID 52 pharmacodynamics 52 IV NSCLC 52 genotypic resistance 52 clinically localized prostate 52 renal tumors 52 CUSTOM II 52 fosbretabulin 52 INSPIRE Trial Phase III 52 Left Ventricular Dysfunction 52 ATACAND 52 HNSCC 52 ximelagatran 52 CTRC AACR San Antonio 52 XIENCE V PROMUS Stent 52 Tocilizumab 52 EOquin TM 52 dosage regimens 52 NEVO RES 52 kidney transplant recipients 52 PROTECT II 52 metastatic hormone refractory 52 Multicenter Randomized 52 HYVET 52 pelvic lymph node dissection 52 Phase III randomized placebo 52 APTIVUS r 52 neratinib 52 Onrigin 52 Phase #b/#a trial 52 AEG# 52 bioabsorbable stent 52 rALLy trial 52 galiximab 52 Meta Analysis 52 CYPHER R Stent 52 Acute Coronary Syndromes 52 immunomodulatory therapy 51 atherothrombosis 51 elacytarabine 51 teriflunomide 51 Blinatumomab 51 SCIg 51 radical nephrectomy 51 PreCISe 51 tibolone 51 thorough QT 51 hyperphenylalaninemia HPA due 51 journal Lancet Neurology 51 comparator arm 51 AACR San Antonio 51 PROactive Study 51 sorafenib Nexavar 51 CHAMPION PLATFORM 51 Faslodex 51 #mg/day [001] 51 adjuvant therapy 51 Phase IIb trials 51 Allovectin 7 ® 51 LibiGel Phase III 51 paclitaxel poliglumex 51 AVAiL 51 ASCO Annual Meeting 51 underwent surgical resection 51 myoblast therapy 51 adrenalectomy 51 KLRI 51 SPIRIT FIRST 51 axillary lymph node dissection 51 Longitudinal Study 51 Angiographic 51 logistic regression models 51 Phase 2a 51 Phase 2b clinical trials 51 NEVO 51 stage IIIB 51 Ophena 51 GEM OS2 51 multidose 51 subtrochanteric 51 recurrent metastatic 51 TAXUS ARRIVE 51 multivariate analyzes 51 AVOREN 51 USA UroToday.com 51 papillary renal cell carcinoma 51 crizotinib PF # 51 European Sepsis Trial 51 corrected QT interval 51 Arteriosclerosis Thrombosis 51 trastuzumab Herceptin ® 51 eprotirome 51 gene expression profiles 51 COPAXONE R 51 Azedra 51 invasive candidiasis 51 Acute Coronary Syndromes ACS 51 ELONVA 51 safety tolerability pharmacokinetics 51 Dupuytren Contracture 51 Phase III Clinical Trials 51 AZILECT ® 51 hepatocellular carcinoma 51 cinacalcet 51 investigational drug 51 dose escalation phase 51 Candesartan 51 ug dose 51 Randomised Study 51 dose regimens 51 Osteoporotic Fractures 51 vitro experiments 51 hereditary deficiency 51 Response Evaluation Criteria 51 Randomized clinical trials 51 bowel capsule endoscopy 51 Halaven 51 rt PA 51 cytoreductive surgery 51 prospectively enrolled 51 ARCOXIA 51 rFSH 51 Neo Bladder Augment 51 lexidronam injection 51 MIVI TRUST 51 TAXUS stent 51 liver transplantations 51 underwent CABG 51 Dacogen injection 51 sirolimus eluting stent 51 ACCLAIM trial 51 immunosuppressive regimen 51 SCCHN 51 ongoing Phase 1b 51 Co Principal Investigator 51 Study Evaluating 51 carotid stents 51 RezularTM 51 mRCC 51 Endeavor drug eluting 51 CYPHER R stent 51 aromatase inhibitor therapy 51 ICD therapy 51 undergoing coronary angiography 51 TASQ 51 NMIBC 51 Coronary Artery Bypass Graft 51 Augment Injectable 51 General Psychiatry 51 vitro studies 51 NOX E# 51 journal Biological Psychiatry 51 CORD II 51 antiepileptic drug 51 Logistic regression 51 patientswith 51 SYMMETRY trial 51 dosing cohort 51 Desmoteplase 51 Percutaneous Coronary Intervention 51 MADIT 51 Vimpat ® lacosamide 51 boosted protease inhibitor 51 Millennium Cohort Study 51 ezetimibe simvastatin 51 metastatic RCC 51 BETAS 51 ganaxolone 51 secondary efficacy endpoint 51 drug eluting stent DES 51 epidemiological studies 51 Overactive Bladder OAB 51 postoperative radiotherapy 51 ZoMaxx 51 bladder augmentation 51 direct thrombin inhibitor 51 oral diclofenac 51 gefitinib Iressa 51 refractory acute myeloid 51 renal biopsy 51 Protelos 51 Xelox 51 factorial design 51 nonmetastatic prostate cancer 51 RAPAFLO R 51 mCRC patients 51 Cohort Study MACS 51 Zavesca R 51 Multi MERCI 51 PTNS 51 Kantarjian 51 nondiabetic patients 51 previously untreated follicular 51 cohort 51 BLA submission 51 BJU International 51 pralatrexate injection 51 glatiramer acetate 51 paricalcitol 51 relapsed myeloma 51 Pre RELAX AHF 51 coronary intervention 51 preoperative chemotherapy 51 refractory CLL 51 Tyrima 51 relapsing remitting multiple sclerosis 51 Xience V stent 51 Vertos II 51 BCR ABL inhibitor 51 XIENCE V demonstrated 51 PD2i ® 51 tesmilifene 51 Nexavar sorafenib 51 ELBW infants 51 Diabetic Macular Edema 51 adjuvant radiotherapy 51 Circulatory Support 51 weekly subcutaneous injections 51 secondary efficacy endpoints 51 stenoses 51 trastuzumab emtansine T DM1 51 Ozarelix 51 Azacitidine 51 HCV NS5B polymerase 51 SNT MC# 51 Carotid artery stenting 51 CLARITY TIMI 51 candesartan cilexetil 51 KRN# 51 Electroencephalography 51 Vascugel ® 51 noninferior 51 onset AF 51 Phase #/#a trial 51 prognostic significance 51 Zarnestra 51 ACOMPLIA R 51 undetectable HBV DNA 51 CANCIDAS 51 diabetic neuropathic pain 51 ablation procedures 51 NCIC CTG 51 Thoracic Oncology

Back to home page